Current Report Filing (8-k)
October 20 2022 - 07:12AM
Edgar (US Regulatory)
false 0001827506 0001827506 2022-10-20
2022-10-20
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 20,
2022
TALARIS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware |
|
001-40384 |
|
83-2377352 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
|
93 Worcester St.
Wellesley, Massachusetts
|
|
02481 |
|
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: 502
398-9250
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.0001 par value per
share |
|
TALS |
|
The NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On October 20, 2022, Talaris Therapeutics, Inc. issued a press
release entitled “Talaris Therapeutics Provides Update on
FREEDOM-1 Phase 3 Clinical
Trial.” A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by
reference.
| Item 9.01 |
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Talaris Therapeutics, Inc. |
|
|
|
|
| Date: October 20, 2022 |
|
|
|
By: |
|
/s/ Scott Requadt
|
|
|
|
|
|
|
Scott Requadt
President and Chief Executive Officer |
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jan 2023 to Feb 2023
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Feb 2022 to Feb 2023
